Boston Scientific Corporation BSX
At closeNov 3, 2026, 5:20 PM EST
After hours · Nov 3, 5:20 PM ET
- YTD
- -54.38%
- 1 year
- -55.88%
- Market cap
- 63.04B
- Revenue (ttm)
- 21.07B
- Profit margin
- 16.62%
- EPS (ttm)
- 2.37
- Shares out
- 1.45B
- P/E ratio
- 18.35
- Forward P/E
- 13.89
- YTD return
- -54.38%
- 1-year return
- -55.88%
- Volume
- 18.77M
- Avg volume
- 19.63M
- Open
- 43.87
- Previous close
- 44.32
- Day's range
- 43.22 – 44.62
- 52-week range
- 39.57 – 105.65
- Beta
- 0.58
- Analysts
- Buy
- Price target
- 49.60 (+14.0%)
- Earnings date
- Feb 3, 2027
2Y -41.22 (-48.65%)
Key statistics
- Enterprise value
- 76.56B
- PEG ratio
- 0.75
- Price / sales
- 2.99
- Price / book
- 2.52
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 1.40%
- Free cash flow
- 0
- Total cash
- 539.00M
- Total debt
- 12.62B
- Return on equity
- 14.32%
- Short % of float
- 2.81%
- 50-day average
- 44.67
- 200-day average
- 56.29
Analyst view
Consensus: buy
- Target (low)
- 41.00
- Target (mean)
- 49.60
- Target (high)
- 60.00
- Strong buy6
- Buy14
- Hold11
- Sell0
- Strong sell0
Next earnings
Feb 3, 2027
Expected Feb 3, 2027. Consensus EPS estimate 0.77555.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 3, 2027 | Dec 30, 2026 | 0.79 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | 0.727 | 0.73 | 0.00 | +0.41% |
| Jul 29, 2026 | Jun 30, 2026 | 0.835 | 0.86 | +0.03 | +2.99% |
| Apr 22, 2026 | Mar 31, 2026 | 0.788 | 0.80 | +0.01 | +1.52% |
| Feb 4, 2026 | Dec 31, 2025 | 0.781 | 0.80 | +0.02 | +2.43% |
| Oct 22, 2025 | Sep 30, 2025 | 0.714 | 0.75 | +0.04 | +5.04% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | TD Cowen | down | Buy | Hold |
| Oct 30, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Oct 29, 2026 | Jefferies | down | Buy | Hold |
| Oct 29, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 29, 2026 | Bernstein | main | Outperform | Outperform |
| Oct 29, 2026 | RBC Capital | main | Outperform | Outperform |
About Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- bostonscientific.com
News
Is BSX Worth Buying Now as Low Valuation Meets Weak Earnings Growth? 
Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock 
SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints 
Intuitive Surgical vs. Boston Scientific: Which Stock Is a Better Buy Now? 
TD Cowen Downgrades Boston Scientific to Hold, Lowers Price Target to $46 
Barclays Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $45 
Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte. 
New Strong Sell Stocks for October 30th - Jefferies Downgrades Boston Scientific to Hold, Lowers Price Target to $46
- Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $48
Your note
Sign in to keep a note on BSX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRENNAN DANIEL J | Chief Financial Officer | Sale | Feb 18, 2025 | 225,808 |
| BROWN VANCE R | General Counsel | Stock Award(Grant) | Feb 12, 2026 | 54,244 |
| BUTCHER ARTHUR C | Officer | Conversion of Exercise of derivative security | Apr 30, 2026 | 77,115 |
| CARRUTHERS WENDY | Officer | Sale | Dec 1, 2024 | 29,308 |
| FITZGERALD JOSEPH MICHAEL | Officer | Stock Award(Grant) | Feb 12, 2026 | 219,141 |
| LUDWIG EDWARD J. | Director | Purchase | Jul 30, 2026 | 30,359 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.95% | 129,680,916 | 5.64B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.70% | 97,087,553 | 4.22B | Jun 29, 2026 |
| State Street Corporation | 4.84% | 70,111,196 | 3.05B | Jun 29, 2026 |
| Primecap Management Company | 3.49% | 50,520,914 | 2.20B | Jun 29, 2026 |
| FMR, LLC | 3.15% | 45,702,845 | 1.99B | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.31% | 33,440,102 | 1.45B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.26% | 47,181,284 | 2.05B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.66% | 38,518,788 | 1.68B | Jun 29, 2026 |
| VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund | 2.13% | 30,831,039 | 1.34B | Jun 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.33% | 19,294,226 | 839.30M | Aug 30, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 19,310,588 | 840.01M | Sep 29, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.23% | 17,894,864 | 778.43M | Sep 29, 2026 |